SnowBrand Evoxac
Executive Summary
Daiichi Pharmaceuticals' 100-rep sales force will promote cevimeline for the treatment of dry mouth symptoms in patients with Sjogren's syndrome. Evoxac, expected to launch in early April, will be manufactured by Yamanouchi Pharma Technologies, Inc. (1"The Pink Sheet" Jan. 17, p. 25)
You may also be interested in...
SnowBrand Treatment For Sjogren's Symptoms Evoxac Will Launch In Spring
SnowBrand Pharmaceuticals anticipates a spring launch for Evoxac (cevimeline), approved Jan. 11 for treatment of dry mouth symptoms in patients with Sjogren's syndrome.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials